Antimicrobial resistance, one of the world’s biggest killers, has reached an alarming tipping point.
Changing the way antibiotics are developed and accessed.
A public-health driven model to tackle AMR.
Our latest news and resources.
Protecting people from the rise and spread of drug-resistant infections.
Supporting efforts to ensure the right antibiotics are developed and reach the people who need them.
2025年12月20日
スイスに本部を置く非営利団体のグローバル抗菌薬研究開発パートナーシップ(GARDP)はこのほど、りん病の新たな抗菌薬が米食品医薬品局(FDA)の承認を得たと発表した。世界初となる飲み薬で、りん病の薬が承認されたのは数十年ぶり。りん病は既存の抗菌薬に耐性をもつ耐性菌が広がっており、世界的な課題となっていた。
Receive updates on GARDP's efforts to transform lives and counter antibiotic resistance around the world.
Personal Information - Select salutation - Mrs Mr Mx Dr Prof
Email *
First Name
Last Name
Your organization/company
Desired content * General Communications Scientific Affairs & REVIVE
By ticking the box you confirm you agree to hearing from GARDP. We will use the information you provide with this form to email you updates on our work.